Stephanie Ascher | Stern, Investor Relations |
Bryan Stuart | President & Chief Executive Officer |
Judy Dunn | President, Research & Development |
Esther Rajavelu | Chief Financial Officer |
Paul Bruno | Executive Director, Corporate Development |
Judah Frommer | Credit Suisse |
Ted Tenthoff | Piper Sandler |
Dae Gon Ha | Stifel |
Matt Biegler | Oppenheimer |
Joseph Schwartz | SVB |
Yatin Suneja | Guggenheim |
Good morning, and welcome to the Fulcrum Therapeutics Second Quarter 2022 Conference Call. Currently all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. Please note today's conference is being recorded. I would now like to turn the call over to Stephanie Ascher from Stern Investor Relations.